Crescent Biopharma (GYRE) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Crescent Biopharma had a P/E ratio of 127.65 (up from 85.93), return on equity of 8.2% (down from 20.2%), debt-to-equity of 0.01 (down from 0.02) and a current ratio of 5.60 (up from 3.32). A current ratio of 5.60 means current assets exceed current liabilities.

Crescent Biopharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Valuation Ratios
P/E Ratio	127.65	85.93	-	-	56.88
Forward P/E	32.84	-	-	-	-
P/S Ratio	5.50	9.82	17.34	-	3.89
P/B Ratio	4.51	10.55	25.07	-	0.70
Price/Tangible Book	6.42	16.85	-	-	22.16
Price/FCF	-	-	113.23	-	-
Price/OCF	635.33	-	75.99	-	-
Enterprise Value Ratios
EV/Revenue	5.30	9.93	17.15	-	-2.17
EV/EBITDA	44.13	58.96	95.72	-	0.18
EV/EBIT	53.81	64.73	101.27	-	0.18
EV/FCF	-	-	111.98	-	0.19
Profitability & Returns
Return on Equity (ROE)	8.21%	20.24%	-113.45%	-	-150.11%
Return on Assets (ROA)	4.93%	8.38%	11.93%	-	-116.80%
Return on Invested Capital (ROIC)	9.58%	21.08%	41.31%	8.85%	-
Return on Capital Employed (ROCE)	7.80%	15.30%	19.90%	12.70%	-148.28%
Leverage & Solvency Ratios
Debt/Equity	0.01	0.02	0.01	0.01	0.01
Debt/EBITDA	0.06	0.09	0.02	0.06	-
Debt/FCF	-	-	0.02	0.11	-
Liquidity Ratios
Current Ratio	5.60	3.32	2.85	4.06	3.63
Quick Ratio	4.58	2.64	2.49	3.33	3.44
Efficiency Ratios
Asset Turnover	0.80	0.87	1.13	-	0.10
Inventory Turnover	0.66	0.73	0.89	-	-
Yield & Distribution Ratios
Earnings Yield	0.78%	1.16%	-4.72%	-	1.76%
FCF Yield	-0.03%	-0.57%	0.88%	-	-
Buyback Yield	-0.87%	-55.39%	13.02%	-	-5117.44%
Total Return	-	-	-	-	-5117.44%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Crescent Biopharma Financial Ratios

What is Crescent Biopharma's P/E ratio?

Crescent Biopharma's P/E ratio was 127.65 for fiscal 2025 (period ended Dec 31, 2025). It was 85.93 a year earlier.

What is Crescent Biopharma's return on equity?

Crescent Biopharma's return on equity (ROE) was 8.2% for fiscal 2025 (period ended Dec 31, 2025). It was 20.2% a year earlier.

What is Crescent Biopharma's debt-to-equity ratio?

Crescent Biopharma's debt-to-equity ratio was 0.01 for fiscal 2025 (period ended Dec 31, 2025). It was 0.02 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition